文献速递心外重症与机械循环支持

Impella CP 在急性心梗与心衰心源性休克中的结局:CSWG 注册研究

Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group.
PubMed 文献 · J Heart Lung Transplant · 2025-08-20

基于国际多中心心源性休克工作组注册,分析 2019–2024 年 1,486 例使用 Impella CP 的患者,比较 AMI-CS 与 HF-CS 的基线、器械暴露与并发症。HF-CS 出院生存率高于 AMI-CS(59.7% vs 49.8%,p<0.001),总器械数量与院内死亡、肢体缺血和出血显著相关。

要点

  • HF-CS 患者出院生存率高于 AMI-CS(59.7% vs 49.8%,p<0.001)。
  • 使用≥2 个其他器械者生存率最低(43.8%)。
  • 总器械数量与院内死亡、肢体缺血和出血显著相关。

核心结论

  • HF-CS 与 AMI-CS 在基线特征、器械暴露和院内并发症上的差异可能影响 Impella CP 支持患者的结局。

研究设计与样本

  • 心源性休克工作组注册研究,纳入 36 个国际中心 2019–2024 年使用 Impella CP 的 CS 患者,按病因和机械支持器械暴露分组比较。

主要发现

  • 共分析 1,486 例 CS 患者,其中 AMI-CS 占 57.9%,HF-CS 占 34.9%。
  • HF-CS 患者较 AMI-CS 更年轻(60 vs 64 岁,p<0.001),慢性肾病比例更高(26.4% vs 13.6%,p<0.001)。
  • Impella CP 单用占 38.3%,CP+ECMO 占 23.1%,CP+≥2 个其他器械占 20.4%。
  • HF-CS 急性肾损伤多于 AMI-CS(66.5% vs 59.7%,p=0.03),AMI-CS 急性肢体缺血多于 HF-CS(14.4% vs 11.0%,p=0.05)。
  • 出院生存率 53.4%,HF-CS 高于 AMI-CS(59.7% vs 49.8%,p<0.001);≥2 个其他器械者生存率最低(43.8%)。

临床怎么用

  • 对心源性休克患者使用 Impella CP 时应区分 AMI-CS 与 HF-CS 病因,并关注 HF-CS 更高的急性肾损伤风险。
  • 应尽量减少不必要的额外机械支持器械数量,因其与院内死亡、肢体缺血和出血相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Impella CP (Abiomed, Danvers, MA) microaxial flow pumps are commonly used in acute myocardial infarction (AMI) and heart failure (HF) cardiogenic shock (CS). Contemporary data from large, unselected populations are needed to understand differences between these groups. METHODS: The Cardiogenic Shock Working Group registry enrolls patients with CS at 36 international sites. We analyzed patients with Impella CP enrolled from 2019-2024, categorized by CS etiology and mechanical support device exposure. Baseline characteristics, complications, and outcomes were compared. Outcomes included survival to discharge, native heart survival, and heart replacement therapy. Multivariable analysis was performed to identify predictors of in-hospital mortality and complications. RESULTS: A total of 1,486 patients with CS (57.9% AMI-CS, 34.9% HF-CS) and Impella CP were analyzed. Patients with HF-CS were younger (60 vs 64 years; p < 0.001) and more likely to have chronic kidney disease (26.4% vs 13.6; p < 0.001) than those with AMI-CS. Impella CP alone was used in 38.3%, CP+ extracorporeal membrane oxygenation in 23.1%, and CP + ≥2 other devices in 20.4%. Acute kidney injury was more common in HF-CS than AMI-CS (66.5% vs 59.7%, p = 0.03) and acute limb ischemia more common in AMI-CS than HF-CS (14.4% vs 11.0%; p = 0.05). Survival to discharge was 53.4% and was higher in HF-CS than AMI-CS (59.7% vs 49.8%; p < 0.001). Those with ≥2 other devices had the lowest survival (43.8%). Total device number was significantly associated with in-hospital mortality, limb ischemia, and bleeding. CONCLUSIONS: Differences in baseline characteristics, device exposure, and hospital complications between patients with HF-CS and AMI-CS supported by Impella CP may influence outcomes.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Carnicelli AP, Sinha SS, Li S, et al. Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group. J Heart Lung Transplant. 2025. PMID: 40846118. doi:10.1016/j.healun.2025.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。